Nitrosamines, Headspace GC-MS, Pharmaceutical Drug Products, Validation, Impurities, Carcinogens, angiotensin receptor blockers, Mitigation
Asymmetrical flow field-flow fractionation, high molar mass polyethylene oxide, abuse deterrent formulation, molar mass distribution